Ajanta Soya Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:36 pm

Quick Insight

Ajanta Soya Ltd, operating in the Edible Oils & Solvent Extraction industry, currently trades at a price of 29.3 with a market cap of 236 Cr. The company boasts a P/E ratio of 9.62, indicating a relatively undervalued position. With a robust ROE of 18.8% and a stellar ROCE of 27.5%, Ajanta Soya demonstrates efficient capital utilization. However, the low OPM of 0.04% suggests room for improvement in operational efficiency. The company's healthy balance sheet, highlighted by reserves of 143 Cr and zero borrowings, is a positive sign. Investors should note the moderate P/BV ratio of 2.18x and the comfortable interest coverage ratio of 11.71x, indicating financial stability. In conclusion, while Ajanta Soya shows strong fundamentals, enhancing operational margins could further boost its performance in the market.

Competitors of Ajanta Soya Ltd

All Competitor Stocks of Ajanta Soya Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:15 am

Below is a detailed analysis of the quarterly data for Ajanta Soya Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 312.08 Cr.. The value appears to be declining and may need further review. It has decreased from 388.39 Cr. (Mar 2025) to 312.08 Cr., marking a decrease of 76.31 Cr..
• For Expenses, as of Jun 2025, the value is 311.96 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 382.31 Cr. (Mar 2025) to 311.96 Cr., marking a decrease of 70.35 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 6.08 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 5.96 Cr..
• For OPM %, as of Jun 2025, the value is 0.04%. The value appears to be declining and may need further review. It has decreased from 1.57% (Mar 2025) to 0.04%, marking a decrease of 1.53%.
• For Other Income, as of Jun 2025, the value is 3.74 Cr.. The value appears strong and on an upward trend. It has increased from 1.70 Cr. (Mar 2025) to 3.74 Cr., marking an increase of 2.04 Cr..
• For Interest, as of Jun 2025, the value is 0.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.43 Cr. (Mar 2025) to 0.87 Cr., marking an increase of 0.44 Cr..
• For Depreciation, as of Jun 2025, the value is 0.75 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.76 Cr. (Mar 2025) to 0.75 Cr., marking a decrease of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 2.24 Cr.. The value appears to be declining and may need further review. It has decreased from 6.59 Cr. (Mar 2025) to 2.24 Cr., marking a decrease of 4.35 Cr..
• For Tax %, as of Jun 2025, the value is 20.09%. The value appears to be improving (decreasing) as expected. It has decreased from 23.98% (Mar 2025) to 20.09%, marking a decrease of 3.89%.
• For Net Profit, as of Jun 2025, the value is 1.78 Cr.. The value appears to be declining and may need further review. It has decreased from 5.02 Cr. (Mar 2025) to 1.78 Cr., marking a decrease of 3.24 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.22. The value appears to be declining and may need further review. It has decreased from 0.62 (Mar 2025) to 0.22, marking a decrease of 0.40.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:08 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:57 pm

Below is a detailed analysis of the balance sheet data for Ajanta Soya Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 143.00 Cr.. The value appears strong and on an upward trend. It has increased from 115.00 Cr. (Mar 2024) to 143.00 Cr., marking an increase of 28.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 85.00 Cr. (Mar 2024) to 100.00 Cr., marking an increase of 15.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 259.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 216.00 Cr. (Mar 2024) to 259.00 Cr., marking an increase of 43.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2024) to 46.00 Cr., marking an increase of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2024) to 37.00 Cr., marking an increase of 13.00 Cr..
• For Other Assets, as of Mar 2025, the value is 176.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 28.00 Cr..
• For Total Assets, as of Mar 2025, the value is 259.00 Cr.. The value appears strong and on an upward trend. It has increased from 216.00 Cr. (Mar 2024) to 259.00 Cr., marking an increase of 43.00 Cr..

Notably, the Reserves (143.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Ajanta Soya Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 3.37. This value is below the healthy minimum of 5. It has increased from 0.50 (Mar 24) to 3.37, marking an increase of 2.87.
• For Diluted EPS (Rs.), as of Mar 25, the value is 3.37. This value is below the healthy minimum of 5. It has increased from 0.50 (Mar 24) to 3.37, marking an increase of 2.87.
• For Cash EPS (Rs.), as of Mar 25, the value is 3.73. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 3.73, marking an increase of 2.90.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 19.74. It has increased from 16.24 (Mar 24) to 19.74, marking an increase of 3.50.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 19.74. It has increased from 16.24 (Mar 24) to 19.74, marking an increase of 3.50.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 165.23. It has increased from 127.00 (Mar 24) to 165.23, marking an increase of 38.23.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 5.32. This value is within the healthy range. It has increased from 1.50 (Mar 24) to 5.32, marking an increase of 3.82.
• For PBIT / Share (Rs.), as of Mar 25, the value is 4.97. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 4.97, marking an increase of 3.81.
• For PBT / Share (Rs.), as of Mar 25, the value is 4.51. This value is within the healthy range. It has increased from 0.63 (Mar 24) to 4.51, marking an increase of 3.88.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 3.37. This value is within the healthy range. It has increased from 0.50 (Mar 24) to 3.37, marking an increase of 2.87.
• For PBDIT Margin (%), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 10. It has increased from 1.18 (Mar 24) to 3.21, marking an increase of 2.03.
• For PBIT Margin (%), as of Mar 25, the value is 3.00. This value is below the healthy minimum of 10. It has increased from 0.91 (Mar 24) to 3.00, marking an increase of 2.09.
• For PBT Margin (%), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 10. It has increased from 0.50 (Mar 24) to 2.73, marking an increase of 2.23.
• For Net Profit Margin (%), as of Mar 25, the value is 2.04. This value is below the healthy minimum of 5. It has increased from 0.39 (Mar 24) to 2.04, marking an increase of 1.65.
• For Return on Networth / Equity (%), as of Mar 25, the value is 17.08. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 17.08, marking an increase of 14.00.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.93. This value is within the healthy range. It has increased from 6.78 (Mar 24) to 23.93, marking an increase of 17.15.
• For Return On Assets (%), as of Mar 25, the value is 10.48. This value is within the healthy range. It has increased from 1.86 (Mar 24) to 10.48, marking an increase of 8.62.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 5.60. It has increased from 4.56 (Mar 24) to 5.60, marking an increase of 1.04.
• For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 2.03 (Mar 24) to 2.18, marking an increase of 0.15.
• For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 1.06, marking an increase of 0.26.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 10.82. This value exceeds the healthy maximum of 8. It has increased from 8.55 (Mar 24) to 10.82, marking an increase of 2.27.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 11.71. This value is within the healthy range. It has increased from 2.84 (Mar 24) to 11.71, marking an increase of 8.87.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.43. This value is within the healthy range. It has increased from 1.95 (Mar 24) to 8.43, marking an increase of 6.48.
• For Enterprise Value (Cr.), as of Mar 25, the value is 314.58. It has increased from 193.01 (Mar 24) to 314.58, marking an increase of 121.57.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.18 (Mar 24) to 0.23, marking an increase of 0.05.
• For EV / EBITDA (X), as of Mar 25, the value is 7.35. This value is within the healthy range. It has decreased from 15.97 (Mar 24) to 7.35, marking a decrease of 8.62.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.26, marking an increase of 0.05.
• For Price / BV (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.18, marking an increase of 0.47.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.26, marking an increase of 0.05.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.07, marking an increase of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness